Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation

• Published in: Human reproduction (Oxford) Vol. 8; no. 9; p. 1387
• Main Authors: Duijkers, I J, Vemer, H M, Hollanders, J M, Willemsen, W N, Bastiaans, L A, Hamilton, C J, Thomas, C M, Borm, G F
• Format: Journal Article
• Language: English
• Published: England 01.09.1993
• Subjects: Adult; Biological Assay; Dose-Response Relationship, Drug; Estradiol - blood; Female; Follicle Stimulating Hormone - administration & dosage; Follicle Stimulating Hormone - blood; Humans; Luteinizing Hormone - administration & dosage; Luteinizing Hormone - blood; Ovarian Follicle - physiology; Ovulation Induction - methods; Pregnancy; Progesterone - blood; Ultrasonography, Prenatal; Vagina
• ISSN: 0268-1161
• DOI: 10.1093/oxfordjournals.humrep.a138266

The aim of the present study was to investigate whether reducing the amount of luteinizing hormone (LH) in gonadotrophic preparations impairs follicular growth in in-vitro fertilization (IVF) cycles during suppression of endogenous LH levels. A selected group of 20 IVF patients was randomly divided into two groups. One group was treated with Org 31338 [follicle stimulating hormone (FSH)/LH 3:1], the other group with Metrodin (purified FSH), both during pituitary down-regulation with buserelin. A fixed daily dose of 150 IU FSH i.m. was given. Serum concentrations of FSH, LH, oestradiol and progesterone were determined frequently and serial ultrasound examinations were performed. Multiple follicular growth with concomitant rise of oestradiol levels was observed in all cycles. The duration of the stimulation phase was shorter in the group treated with Org 31338 than in the group treated with Metrodin. The number of follicles and oocytes and the fertilization rate was larger and the mean embryo quality was higher in the Org 31338 group, but the differences did not reach statistical significance. No significant differences were found in hormonal values. In women with normal endocrine profiles, lowering of the LH activity in gonadotrophic preparations during gonadotrophin-releasing hormone agonist treatment results in adequate ovarian stimulation. However, a preparation with some LH needed a shorter stimulation than a purified FSH preparation. Whether the other beneficial effects of Org 31338 also occur in a larger population needs further investigation.